News

Cochrane2d
What are the benefits and risks of sustained-release (long-acting) naltrexone for the treatment of dependence on opioid drugs (addiction)?
Sustained-release naltrexone may slightly increase illicit opioid use and serious adverse events compared to opioid agonists, with uncertain effects on retention and acceptability. It may reduce ...
Cochrane2d
Cochrane seeks Digital Marketing Officer
The Digital Marketing Officer is an exciting new role that reflects the strategic importance of digital marketing to Cochrane ...
Cochrane4d
Do proton pump inhibitors prevent ulcers and stomach discomfort caused by non-steroidal anti-inflammatory drugs?
Compared with placebo, PPIs may have no effect on the presence of global symptoms of dyspepsia and probably result in a slight reduction in global symptoms of dyspepsia scales. PPI probably reduces ...
Cochrane5d
Efecto de una dieta baja en sal sobre la presión arterial y algunas hormonas y lípidos en personas con tensión normal y alta
El documentalista del Grupo Cochrane de Hipertensión (Cochrane Hypertension) buscó ensayos controlados aleatorizados en las siguientes bases de datos hasta abril de 2018 y de nuevo en marzo de 2020: ...
Cochrane6d
Antivirales de acción directa para la hepatitis C crónica
Se buscaron todos los ensayos publicados y no publicados en el Registro de Ensayos Controlados del Grupo Cochrane Hepatobiliar (Cochrane Hepato-Biliary Group Controlled Trials Register), CENTRAL, ...